What smart money is saying about Ascendis Pharma
1 fund in our archive has pitched Ascendis Pharma — most recently Artisan Partners U.S. Small-Cap Growth Strategy in June 2026.
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
Get an email when a fund buys, sells or pitches it
Position history
Between Q3 2025 and Q2 2026, 6 fund letters reported a position in Ascendis Pharma — 3 trimmed or exited.
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q2 2026 | 4 | 0 | 2 | 1 |
| Q3 2025 | 2 | 0 | 1 | 0 |
Fund activity · 6 positions · 3 moves
- June 2026
“In health care, we saw strong earnings and stock returns from biotech drug companies like Argenx and Ascendis Pharma, as well as from life sciences tools and diagnostics innovators such as Twist Bioscience, Guardant Health and Veracyte.”
Ascendis Pharma - June 2026
“Ascendis Pharma is a biotechnology company leveraging its proprietary TransCon® platform to develop differentiated therapies for patients with significant unmet medical needs. Recent results were mixed, with revenue below expectations but EPS meaningfully ahead, supported by R&D leverage and improving operating discipline. Importantly, patient growth for YORVIPATH® remained strong, with more than 1,000 new patients added and enrollment momentum continuing despite temporary revenue headwinds from seasonality, free drug programs and European market access. The early launch of YUVIWEL®, a treatment for a rare bone-growth disorder, also appears encouraging. SKYTROFA®, a long-acting growth hormone therapy for children with growth hormone deficiency, continues to gain share and could benefit from future label expansion. We reduced the position during the quarter after a competitor with an existing treatment for the same rare hormone disorder as YORVIPATH® filed a lawsuit against Ascendis.”
Ascendis Pharma - June 2026
“In health care, we saw strong earnings and stock returns from biotech drug companies like Argenx and Ascendis Pharma, as well as from life sciences tools, diagnostics and drug- delivery-related businesses such as Twist Bioscience, West Pharmaceutical and Veracyte.”
Ascendis Pharma - TrimmedSpyglass Growth StrategyJune 2026
“Top Trims Company Percentage Points Sold Credo Technology Group Holding Ltd -2.73% Ascendis Pharma A/S -2.10% Cadence Design Systems, Inc. -1.41% Net trims for a representative portfolio during the quarter ended June 30, 2026. During the second quarter, the positions that were most significantly trimmed were Credo Technology Group, Ascendis Pharma, and Cadence Design Systems.”
Ascendis Pharma - September 2025
Listed in Artisan US Mid Cap Growth Strategy’s reported holdings.
Ascendis Pharma - September 2025
“Ascendis is a biotech company leveraging its proprietary TransCon™ platform to develop differentiated therapies that address unmet medical needs. This technology enables sustained and predictable drug release while preserving the drug’s original mechanism of action. The launch of Yorvipath®—the first and only hormone replacement therapy for adult hypoparathyroidism—has exceeded expectations, generating revenues of €103 million in Q2 2025, more than double the prior quarter, with over 3,100 patients and 1,500 US prescribers. This strong uptake reinforces our confidence in both Yorvipath® and Ascendis’ broader pipeline. Following the stock’s strong performance this year, we reduced our position to manage concentration risk but continue to view the valuation as compelling.”
Ascendis Pharma
Fund coverage · 1 thesis
Ascendis Pharma uses its TransCon platform to develop differentiated rare-disease therapies, with strong patient growth supporting long-term conviction.
Read the full thesis
Read every full thesis on Ascendis Pharma
Unlock all 1 thesis — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→